2024 TAAB Annual Symposium

he 2024 TAAB Symposium Committee cordially invites you to join the 2-day 2024 Annual TAAB Symposium. This year, our symposium theme is “Biotechnological development trend in U.S : From Bench to Marketing ” The symposium will be held at the Hunter College on November 16–17.
More details regarding the program and speakers can be found on the TAAB Facebook , LinkedIn page, Instagram, Threads, or our website. Please stay tuned for updates on the 2024 TAAB Symposium schedule.

Buy tickets

Speakers

Dr. Lin, also a joint professor at Columbia University , founded Graphen, Inc. in New York in 2017. The company's mission is to develop state-of-the-art AI technology for the well-being of humankind. Before the establishment of Graphen, Inc., Dr. Lin was a chief scientist at IBM Corp and has led large-scale AI projects across multiple countries to enable full-brain functionality through fundamental R&D breakthroughs.
Dr. Lin, also a joint professor at Columbia University , founded Graphen, Inc. in New York in 2017. The company's mission is to develop state-of-the-art AI technology for the well-being of humankind. Before the establishment of Graphen, Inc., Dr. Lin was a chief scientist at IBM Corp and has led large-scale AI projects across multiple countries to enable full-brain functionality through fundamental R&D breakthroughs.
Dr. Ken Takeshita is the Global Head of Research and Development at Daiichi Sankyo, where he leads global clinical development strategies and drives the expansion of the company’s oncology pipeline across multiple regions. With extensive experience in R&D and clinical leadership, Dr. Takeshita has held senior positions at Kite Pharma, Sorrento Therapeutics, Celgene, and Amgen, where he spearheaded breakthrough treatments for solid tumors and blood cancers.
Dr. Ken Takeshita is the Global Head of Research and Development at Daiichi Sankyo, where he leads global clinical development strategies and drives the expansion of the company’s oncology pipeline across multiple regions. With extensive experience in R&D and clinical leadership, Dr. Takeshita has held senior positions at Kite Pharma, Sorrento Therapeutics, Celgene, and Amgen, where he spearheaded breakthrough treatments for solid tumors and blood cancers.
Dr. Yen-Po Chin (Dr. Harvey) Chairman at AGM International Group Co-Founder at Stealth Startup Founding Partner at HYPERIUS BIOTECH
Dr. Yen-Po Chin (Dr. Harvey)
Chairman at AGM International Group
Co-Founder at Stealth Startup
Founding Partner at HYPERIUS BIOTECH

Agenda

463208919_873333721554526_6139112046342939106_n